Purpose: To study the prevalence and effect of smoking on cervical cancer recurrence and mortality in patients undergoing definitive treatment with radiation.
I
n the 5 decades since the Surgeon General's January 1964 landmark pronouncement on the negative impact of tobacco on health, the reduction in smoking among the world's population has averted millions of deaths. Key efforts have included taxes on tobaccos, clean air laws, and mass public education. From the 1960s to today, the prevalence of adult smokers in the United States has fallen significantly. By the second quarter of this century, it is estimated that the number of smokers in the United States will fall to an all-time low of 15% of the adult population. 1 However, among female smokers, the relative and absolute risk of death from smoking is continues to increase. Smoking remains the number 1 preventable cause of premature death in women, and accounts for over 30% of all-cause mortality. 2 Other common health risks associated with smoking includes chronic obstructive lung diseases, stroke, coronary artery disease, and peripheral vascular disease. Smoking has also been linked to other types of malignancies, such as cancer of the lung, colorectum, bladder, kidney, stomach, pancreas, and the cervix. 3 Studies have shown a potential link between smoking and incidence of cervical cancer, especially in setting of concurrent human papillomavirus (HPV) infection. 4, 5 The exact mechanism is unknown, although it is believed to stem from several factors including carcinogens in cigarette smoke, immunosuppression, and poor compliance of smokers to cervical cancer screening. 6 Less is known about the effect of smoking on diseasespecific mortality and overall survival (OS) after a diagnoses of cervical cancer in those treated with brachytherapy as part of their care. Recent publications have suggested that smoking may lead to greater mortality in those patients diagnosed with cervical cancer. 6, 7 In contrast, other survival analyses have not demonstrated such relationship. 8 In the era of treatment and novel therapeutics to improve cervical cancer outcomes, we sought to investigate the effect of former and active smoking, on cervical cancer outcomes. Our study examines the prevalence of smoking among our locally advanced cervical cancer population receiving definitive radiation or chemoradiation therapy followed by brachytherapy, and the impact of smoking on pelvic control (PC), disease-free survival (DFS), and overall survival (OS).
MATERIALS AND METHODS

Patient Characteristics
Between July 2007 and September 2013, 96 patients received radiation and chemotherapy for definitive treatment of locally advanced cervical cancer. Institutional Review Board approval was obtained for the study. Patients were identified as former or active smokers based on their completion of a prospective intake questionnaire at the time of the radiation oncology consultation. Smoking habits were quantified on the basis of the number of packs smoked per day multiplied by the number of years the patient smoked (pack-years).
Tumor Characteristics
Tumor characteristics included stage, histology, and nodal status. Cervical cancers were staged based on the International Federation of Gynecology and Obstetrics staging system. The histology was based on pathology reports and categorized as squamous cell carcinoma, adenocarcinoma, or adenosquamous carcinoma. Positive pelvic and para-aortic lymph nodes were based on radiographic imaging by positron emission tomography/computed tomography (CT), or lymph node surgical staging.
Treatment Procedure
Patients were treated with concurrent chemotherapy consisting of weekly cisplatin 40 mg/m 2 or 5-Fluorouracil 1000 mg/m 2 . They also received external-beam radiation therapy to the entire pelvis using a 4-field conformal technique, or if there were positive para-aortic lymph nodes involved, an extended field radiation technique was used. Radiation was delivered in 5 fractions per week for a total of 45 Gy in 25 fractions. A few patients received a parametrial or lymph node boost, typically consisting of 3 to 5 additional fractions. All patients subsequently underwent intracavitary high-dose-rate brachytherapy using a tandem and ring applicator.
Three-dimensional (3D) Treatment Planning
We used Varian Eclipse BrachyVision (version 8.1) for 3D treatment planning following brachytherapy. The following reference points were identified: International Commission on Radiation Units and Measurements (ICRU) rectal points and Manchester's A and B points. The ICRU rectal point was defined as the point on the lateral plain film 5 mm behind the packing at the level of the tandem ring. A manual optimization was carried out using the planning software with a traditional loading pattern of the tandem and ring. The dose was normalized to point A with the high-dose-rate prescription dose of 6 Gy for 5 fractions or 8 Gy for 3 fractions. From 2007 to the beginning of 2011, the brachytherapy prescriptions were normalized to ICRU point A. Since 2011, our current practice is to normalize to ICRU point A and then using CT-based imaged-guided techniques, manually adjust the dwell times to account for volumetric dose constraints to the high-risk clinical target volume, rectum, sigmoid, and bladder.
Follow-up
Patients were recommended to follow-up in 3-month intervals after finishing radiation therapy. During follow-up patients were asked questions about side effects and underwent a pelvic examination. Patients underwent a postradiation 12-week positron emission tomography scan, and further imaging, such as CT of the abdomen, in setting of symptom concerning for cervical cancer, such as weight loss and abdominal fullness. They also underwent further imaging in setting of positive examination findings, such as palpable lymph nodes or mass per clinical examination.
Statistical Methods
Continuous variables were compared among smoking categories using analysis of variance, except for analyses of number of chemotherapy cycles, which used the KruskalWallis test. The distributions of categorical variables were compared among smoking categories using w 2 tests. Medians for time-to-event outcomes (OS, DFS, and PC) were estimated using the Kaplan-Meier method.
Time-to-event outcomes were analyzed by patient characteristics using Cox proportional hazards models. To obtain estimates of hazard ratios (HRs) when there were no events in a given covariate category, estimation was conducted using penalized likelihood. 9 First, univariate analyses were conducted for each baseline characteristic and time-to-event outcomes; multivariable Cox models for each time-to-event outcome included covariates with a P-value of <0.2 in univariate Cox analyses that also had a P-value of <0.2 for an association with smoking.
Analyses were conducted using the statistical software environment R, version 3.0.1. 10 Penalized likelihood estimation for Cox models was implemented using the R package coxphf, version 1.10, 11 and penalized likelihood estimation for logistic regression models was conducted using the R package logistf, version 1.21. 11 Time-to-event endpoints (OS, DFS, and PC) were analyzed by patient and disease characteristics using multivariable Cox proportional hazards models. PC was defined as time from diagnosis to last follow-up when the patient was free from any recurrence of the cancer. DFS was defined as time from diagnosis to last follow-up when the patient had local or distant metastasis. OS was defined as time from diagnosis to either death or last follow-up.
RESULTS
Patient Characteristics
The study population consisted of 96 patients with an average age of 54. There was no difference between the nonsmokers, or smokers by category (1 to 20 pack-years, vs. 20 y plus) for BMI, performance status, chemotherapy regimen nor cycles, brachytherapy dose, total radiation time, comorbidity index, lymph node status, alcohol use, stage, histology, or use of a parametrial or lymph node boost as shown in Table 1 . There was a statistically significant difference between the nonsmokers and smokers for age, illicit drug use, and ethnicity.
Patient Survival Characteristics
The median follow-up time was approximately 2 years (range, 0 to 6 y). At most recent follow-up, 85 patients (88.5%) were free of local recurrence of cancer and 86 patients (89.6%) were free of distant metastasis. The details on the time to events are shown in Table 2 . On univariate analysis, as shown in Table 3 , the impact of 1 to 20 pack-years smoking history on PC, DFS, and OS relative to nonsmokers was HR = 4.29 (95% confidence interval [CI], 1.36-14.1; P = 0.014), 4.99 (95% CI, 1.21-22.4; P = 0.027), and 4.77 (95% CI, 1.34-17.8; P = 0.017), respectively. For patients with 21 + pack-years smoking history, the impact on PC, DFS, and OS was HR = 6.13 (95% CI, 2.29-18.6; P < 0.001), 7.24 (95% CI, 2.28-29.1; P = 0.001), and 4.21 (95% CI, 1.26-15.4; P = 0.02), respectively, as shown in the univariate analysis in Table 3 . We then controlled for potential confounders in the model, such as age, stage, ethnicity, race, BMI, Karnofsky performance status, lymph node status, chemotherapy receipt, radiation dose, brachytherapy dose, receipt of a parametrial boost, total time of completion of radiation for the multivariate analysis. On multivariate analysis, there remained a significant difference of 1 to 20 pack-years smoking history on OS relative to nonsmokers was HR = 4.68 (95% CI, 1.02-29; P = 0.047). For patients with 21 + pack-years smoking history, there continued to be a negative impact on PC and DFS, with HR = 5.66 (95% CI, 1.7-22.18; P = 0.004) and HR = 6.89 (95% CI, 1.54-42; P = 0.011), respectively, as shown in Table 4 . The Kaplan-Meir survival curves for PC, DFS, and OS are shown in Figures 1 to 3 .
DISCUSSION
Our study shows that active or having a history of smoking decreases PC, DFS, and OS in cervical cancer treated with radiation. Furthermore, in the era of treatment intensification and biological therapeutic strategies to improve cervical cancer outcomes, our data suggest that lifestyle factors contribute significantly to long-term survival. The detrimental effect of smoking was seen in former or current smokers, and there was a relationship to worse survival in those smoking a higher number of cigarettes per day. These data provide the radiation oncologist with tangible data that patients who do not smoke during radiation will live longer and have less recurrences of their cervical cancer. Throughout the last decade there continues to be strides to decrease the death rate in patients with locally advanced cervical cancer with the anticipated discovery and use of novel therapeutics in the field. The addition of systemic therapy to radiation for the treatment of invasive cervical cancer has revolutionized the management and clinical outcome of patients with locally advanced cervical cancer. [12] [13] [14] However, there continue to be subgroups of cervical cancer patients who do not experience a complete response and improved survival conferred by chemoradiation. Most noticeable among these patients are those with nodal metastases or those with advanced stage disease. Therefore, there is a high-risk patient population that will further benefit from efforts aimed at either treatment intensification, or optimization of environmental factors that impact DFS. For example, the role of adjuvant chemotherapy after standard chemoradiation has been shown to improve OS in a recent phase 3 randomized trial in Mexico, and is currently the study arm of a global prospective randomized trial, the OUTBACK trial. 15 However, intensification of therapy is not without potential significant toxicity; patients on the Mexican trial who received adjuvant chemotherapy experienced a higher risk of grade 3 and 4 toxicity, 86.5% versus 46.3%, respectively, P = 0.001. 16 Because of the potential for adverse side effects from treatment intensification and the poor DFS of locally advanced cervical cancer, there have been increasing efforts to target lifestyle and alter environmental factors to improve patient outcomes. Our study shows patients who had a history of smoking at the time of radiation therapy consultation had a decrease in PC, DFS, and OS, allowing an opportunity for outcome improvement We currently know that smoking increases the risk of developing invasive cervical cancer. Winkelstein 17 first postulated smoking to be a risk factor for cervical cancer, publishing this work in 1977. Since then, several studies have confirmed the association between smoking and incidence of cervical cancer, but the exact mechanism by which smoking leads to increased risk for carcinogensis is unknown. 4, 5 Studies have suggested that smoking increases the risk of HPV infection. For example, in a study by Simen-Kapeu et al, 18 smoking was shown to be associated with acquisition of highrisk HPV. This is partially explained by smokers being less compliant with cervical cancer screening and subsequent management. 19 Furthermore, smokers have delayed clearance of HPV infection. 20, 21 Investigations have been performed to determine the effect of smoking on patients with concurrent HPV infection, and the increased risk of developing cervical cancer. One leading theory of enhanced carcinogenesis is that exposure of cervical epithelial cells to nicotine and cotinine causes DNA damage and subsequent increased risk of malignancy. 22, 23 According to Alam et al, 24 benzo[a]pyrene is a major carcinogen found in cigarettes and may also play a significant role. High levels of benzo[a]pyrene were detected in cervical tissues of women smokers and believed to modulate the HPV lifecycle by increasing expression of oncogenes E6 and E7. 25 Smoking is also believed to inhibit the immune system response to HPV, especially T helper lymphocyte, natural killer cell, and immunoglobulin E activity. 26 It is postulated that smoking may lead to more aggressive forms of preinvasive cervical cancer. For example, in a study by McIntyre-Seltman et al, 27 smokers were found to have more rapid development of CIN 3.
It is uncertain why smoking may lead to increased cervical cancer mortality. Hypoxia and tumor size are significant adverse prognostic factors of DFS in patients with cervical cancer, with a high-risk group of patients with bulky hypoxic tumors having an increased risk of relapse and death. 28 Subsequently, Fyles et al 8 examined the effect of smoking on tumor hypoxia and cervical cancer outcomes as tumor hypoxia is associated with an increased risk of cervical tumor recurrence and death. Tumor oxygenation was determined using the Eppendorf polarographic oxygen electrode, and tumor oxygenation is represented by the hypoxic proportion HP5 (% of pO 2 measurements <5 mm Hg). 8 There was no significant association between smoking and tumor hypoxia (P = 0.3). 8 They conclude that there was no significant association between smoking and tumor hypoxia, treatment response, or survival in this study of patients with cervix cancer. In addition, there is an association between p53 mutation and smoking. p53 mutations are frequent in tobacco-related cancers and the mutation load is often higher in cancers from smokers than from nonsmokers. 29 Carcinogens from tobacco smoke can also cause G to T transversion mutations, which occur when the substitution of a purine for a pyrimidine or vice versa. This type of mutation alters the chemical structure of DNA dramatically and is has increased potential for degeneracy due to the wobble position of DNA being less tolerant to transversions then, for example, transitions. In addition, data suggest that p53 mutations in certain cancers can be attributed to direct DNA damage from cigarette smoke carcinogens rather than to selection of preexisting endogenous mutations. 29 The results of our study are consistent with those previously published in the literature, for smokers to have a statistically significant higher HR than nonsmokers for both DFS and OS in cervical cancer. In a study by Coker et al, 6 women smokers were 35% more likely to die of any cause and 21% more likely to die of cervical cancer-related cause. In addition, in an analysis of the Gynecology Oncology Group trial 165, a phase III study (GOG 165) in which patients were randomly allocated to receive radiation plus either cisplatin or 5-Fluorouracil, smoking behavior was ascertained using an administered questionnaire and by quantifying urine cotinine concentration. 7 Compared with nonsmokers, median survival was 15 months shorter for reported smokers and 20 months shorter for cotinine-derived smokers (P < 0.01). 7 After adjusting for covariates, a significant increase in the risk of death (but not disease progression) was observed for reported smokers (HR = 1.51; 95% CI, 1.01-2.27; P = 0.04). 7 Our study findings augment these findings in the literature as we found a linear relationship between the number of smoking pack-years and cervical cancer recurrence and mortality. Patients with 21 + smoking pack-years had higher HR of DFS and OS compared with patients with r20 smoking packyears, suggesting a role for intervention on the number of cigarettes consumed during the difficult process of smoking cessation.
The effect of smoking on detrimental outcomes exhibited in our data is not limited to cervical cancer. Head and neck cancer, a cancer which has many similarities to cervical cancer in the tempo of disease progression, and therapeutic options including definitive concurrent chemoradiotherapy, also has data in the literature that smoking decreases survival. 16, 30, 31 In a report of patients with head and neck squamous cell cancer, Chen et al, 16 showed that active smokers had significantly inferior 5-year OS (23% vs. 55%), locoregional control (58% vs. 69%), and DFS (42% vs. 65%) compared with the former smokers who had quit before radiation therapy (P < 0.05).
The main limitation of our study is a retrospective cohort from a single institution. The primary aim of our study is to examine the effect of smoking status on outcomes, and offer an opportunity for cervical cancer mortality improvement. The questionnaires issued at the time of radiation oncology consultation were patient reported, and therefore could be subject to underreporting of the smoking status or pack-years smoked. In addition, this study examined the effects of smoking on cervical cancer outcomes and did not specifically examine the effect of former versus active smoking as in the literature, but we know that few smokers with cervical cancer quit during treatment. 7 The mechanisms of effect on treatment outcome may be different between active and former smokers. Former smoking and carcinogenesis may lead to bulkier and more advanced stage tumors, whereas current smoking may increase radioresistance and hypoxia. In addition, we are unable to determine the varying detrimental effect of smoking before radiation versus the effect of smoking during radiation given the limitation of our questionnaire.
In smokers, competing causes of death are a confounding issue as smoking increases both cardiovascular death and further complications from oncology treatments. 32 According to Coker and colleagues, the increased cervical cancer mortality associated with smoking may be attributed to causes separate from cervical cancer. For example, smoking has strong association with cardiovascular events and stroke. 33 We did, however, control our data for socioeconomic and treatment-related factors that could influence outcomes, such as the concurrent use of chemotherapy, alcohol, drugs, and overall treatment time.
Although subject to the limitations of a retrospective review, our data show that lifestyle habits influence cervical cancer outcomes. This finding allows an opportunity for improvement in patients who identify themselves as active smokers during radiation. Various methods to encourage smoking cessation are available, including contracts signed by the patient upon starting radiation. 34 There is a dirth of data on the effect of smoking intervention, and smoking cessation on cervical cancer morbidity and mortality. Indeed, more studies are needed to determine the effect and effectiveness of smoking cessation efforts on cervical cancer mortality. Novel smoking cessation intervention, effectiveness, and potential outcome improvement are being developed by our group.
Our data show that smoking increases the risk of cancer recurrence and mortality in patients with locally advanced cervical cancer. Our data illustrate compelling evidence to support the role of increased efforts promoted at smoking cessation during radiation and brachytherapy in active smokers.
